A study with a dual APRIL/BAFF inhibitor in patients with SLE reported that the incidence of treatment-emergent adverse events and infections was comparable between the two groups; however, the levels of CD19+ B cells were reduced by approximately 50% following treatment [76], which could be a safety liability for patients. This evidence concerns the gene TNFSF13 and infection.